In patients with BTK-pretreated chronic lymphocytic leukemia (CLL), AbbVie and Roche’s Venclexta (venetoclax) is the drug to ...

New data presented at EHA 2026 showed durable long-term outcomes for BRUKINSA in patients aged 80 and older, while additional ...

New findings presented at ASCO 2026 show that a CAR-T cell therapy called Breyanzi (lisocabtagene maraleucel) is producing ...

Eli Lilly and Co. LLY said Sunday that its Phase 3 BRUIN CLL-322 trial met its primary endpoint, with the addition of ...

Lilly's announces results from Phase III clinical trial of Jaypirca: Indianapolis Tuesday, June 16, 2026, 10:00 Hrs [IST] Eli Lilly and Company announced results from the Phase 3 ...

Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic ...

AbbVie (NYSE: ABBV) today announced new Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association (EHA) 2026 Congress taking place June 11-14 in Stockholm, ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and ...

B-cell chronic lymphocytic leukemia (CLL) occurs when abnormal B cells accumulate in the bone marrow and blood. This crowds out healthy blood cells and weakens the body’s ability to fight infections.

Chronic lymphocytic leukemia (CLL) treatment options depend on your diagnosis. In earlier stages, “watchful waiting” may be recommended. More advanced CLL may require a combination of therapies.

Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...

Chronic lymphocytic leukemia (CLL) is a type of blood cancer in which the bone marrow makes too many lymphocytes, a type of white blood cell. CLL can affect people of any age or gender but is more ...